Veradermics, Incorporated (MANE)
NYSE: MANE · Real-Time Price · USD
48.62
+1.27 (2.68%)
Mar 5, 2026, 4:00 PM EST - Market closed
Veradermics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Selling, General & Admin | 6.48 | 3.5 | 2.35 |
| Research & Development | 48.82 | 23.28 | 14.97 |
| Operating Expenses | 55.31 | 26.78 | 17.32 |
| Operating Income | -55.31 | -26.78 | -17.32 |
| Interest Expense | -0.29 | -0.59 | -0.04 |
| Interest & Investment Income | 0.87 | 0.48 | 0.87 |
| Other Non Operating Income (Expenses) | 0.93 | 0.39 | - |
| Pretax Income | -53.81 | -26.49 | -16.49 |
| Net Income | -53.81 | -26.49 | -16.49 |
| Preferred Dividends & Other Adjustments | 7.83 | 0.82 | - |
| Net Income to Common | -61.64 | -27.3 | -16.49 |
| Shares Outstanding (Basic) | 1 | 1 | 1 |
| Shares Outstanding (Diluted) | 1 | 1 | 1 |
| EPS (Basic) | -83.10 | -37.05 | -22.38 |
| EPS (Diluted) | -83.10 | -37.05 | -22.38 |
| EBIT | -55.31 | -26.78 | -17.32 |
Source: S&P Capital IQ. Standard template.
Financial Sources.